PKC/NADPH oxidase are involved in the protective effect of pioglitazone in high homocysteine-induced paracrine dyfunction in endothelial progenitor cells

American Journal of Translational Research

Volumn 9, Issue 3, 2017, Pages 1037-1048

  Xu, Shengjie ^a   Zhao, Yanbo ^a   Jin, Chongying ^a   Yu, Lu ^a   Ding, Fang ^b   Fu, Guo Sheng ^a   Zhu, Jun Hui ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG HOSPITAL   (China)

Author keywords

p67phox; Paracrine cytokines; Reactive oxygen species; siRNA

Indexed keywords

HOMOCYSTEINE; INTERLEUKIN 8; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL ISOLATION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

EID: 85016415789     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Di Santo S, Yang Z, Wyler von Ballmoos M, Voelzmann J, Diehm N, Baumgartner I and Kalka C. Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One 2009; 4: e5643.
2. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM and Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39: 733-742.
3. He T, Peterson TE and Katusic ZS. Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8. Am J Physiol Heart Circ Physiol 2005; 289: H968-972.
4. Abe Y, Ozaki Y, Kasuya J, Yamamoto K, Ando J, Sudo R, Ikeda M and Tanishita K. Endothelial progenitor cells promote directional three-dimensional endothelial network formation by secreting vascular endothelial growth factor. PLoS One 2013; 8: e82085.
5. Chen JZ, Zhu JH, Wang XX, Xie XD, Sun J, Shang YP, Guo XG, Dai HM and Hu SJ. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol 2004; 36: 233-239.
6. Zhu J, Wang X, Chen J, Sun J and Zhang F. Reduced number and activity of circulating endothelial progenitor cells from patients with hyperhomocysteinemia. Arch Med Res 2006; 37: 484-489.
7. Zhu JH, Chen JZ, Wang XX, Xie XD, Sun J and Zhang FR. Homocysteine accelerates senescence and reduces proliferation of endothelial progenitor cells. J Mol Cell Cardiol 2006; 40: 648-652.
8. Bao XM, Wu CF and Lu GP. Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK. Atherosclerosis 2010; 210: 114-121.
9. Latacha KS and Rosenquist TH. Homocysteine inhibits extra-embryonic vascular development in the avian embryo. Dev Dyn 2005; 234: 323-331.
10. Zhang C, Hu JJ, Xia M, Boini KM, Brimson CA, Laperle LA and Li PL. Protection of podocytes from hyperhomocysteinemia-induced injury by deletion of the gp91phox gene. Free Radic Biol Med 2010; 48: 1109-1117.
11. Lee I, Lee H, Kim JM, Chae EH, Kim SJ and Chang N. Short-term hyperhomocysteinemia-induced oxidative stress activates retinal glial cells and increases vascular endothelial growth factor expression in rat retina. Biosci Biotechnol Biochem 2007; 71: 1203-1210.
12. Jiang X, Yang F, Tan H, Liao D, Bryan RM Jr, Randhawa JK, Rumbaut RE, Durante W, Schafer AI, Yang X and Wang H. Hyper-homocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 2005; 25: 2515-2521.
13. Siow YL, Au-Yeung KK, Woo CW and O K. Homocysteine stimulates phosphorylation of NADPH oxidase p47phox and p67phox subunits in monocytes via protein kinase Cbeta activation. Biochem J 2006; 398: 73-82.
14. Werner C, Kamani CH, Gensch C, Bohm M and Laufs U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007; 56: 2609-2615.
15. Spigoni V, Picconi A, Cito M, Ridolfi V, Bonomini S, Casali C, Zavaroni I, Gnudi L, Metra M and Dei Cas A. Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance. PLoS One 2012; 7: e48283.
16. Gensch C, Clever YP, Werner C, Hanhoun M, Bohm M and Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 2007; 192: 67-74.
17. Imanishi T, Kobayashi K, Kuroi A, Ikejima H and Akasaka T. Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell. Hypertens Res 2008; 31: 757-765.
18. Krenning G, van Luyn MJ and Harmsen MC. Endothelial progenitor cell-based neovascularization: implications for therapy. Trends Mol Med 2009; 15: 180-189.
19. Cacciapuoti F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis 2011; 32: 82-88.
20. Dalal S, Parkin SM, Homer-Vanniasinkam S and Nicolaou A. Effect of homocysteine on cytokine production by human endothelial cells and monocytes. Ann Clin Biochem 2003; 40: 534-541.
21. Zhang Q, Li Q, Chen Y, Huang X, Yang IH, Cao L, Wu WK and Tan HM. Homocysteine-impaired angiogenesis is associated with VEGF/VEGFR inhibition. Front Biosci (Elite Ed) 2012; 4: 2525-2535.
22. Cheng Z, Jiang X, Pansuria M, Fang P, Mai J, Mallilankaraman K, Gandhirajan RK, Eguchi S, Scalia R, Madesh M, Yang X and Wang H. Hyperhomocysteinemia and hyperglycemia induce and potentiate endothelial dysfunction via mu-calpain activation. Diabetes 2015; 64: 947-959.
23. Sirker A, Zhang M and Shah AM. NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies. Basic Res Cardiol 2011; 106: 735-747.
24. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
25. Werner C, Gensch C, Poss J, Haendeler J, Bohm M and Laufs U. Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis. Atherosclerosis 2011; 216: 23-34.
26. Yu HC, Feng SF, Chao PL and Lin AM. Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system. Neuropathol Appl Neurobiol 2010; 36: 612-622.
27. Yang HB, Zhao XY, Zhang JY, Du YY and Wang XF. Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance. Diabet Med 2012; 29: 359-365.
28. Vijay SK, Mishra M, Kumar H and Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol 2009; 46: 27-33.
29. Huang PH, Sata M, Nishimatsu H, Sumi M, Hirata Y and Nagai R. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother 2008; 62: 46-52.
30. Hontecillas R and Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 2007; 178: 2940-2949.
31. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM and Dimmeler S. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. Blood 2004; 104: 3591-3597.